Expressive

rs10799590 (CNIH3): Opioid Dependence Variant

Key takeaways

  • The A allele of rs10799590 in CNIH3 was associated with roughly 36% lower odds of progressing from opioid misuse to full dependence (OR 0.64, 95% CI 0.55-0.74)
  • This association reached genome-wide significance (p=4.30×10^-9) and was replicated in two independent cohorts
  • CNIH3 encodes a helper protein for AMPA-type glutamate receptors, brain signaling proteins involved in reward and learning
  • A allele carriers showed greater amygdala dampening in response to threatening faces, a phenotype linked to psychological resilience
  • Animal data across 23 mouse strains independently supported this gene region's role in physical morphine dependence

Key takeaways

  • The A allele of rs10799590 in CNIH3 was associated with roughly 36% lower odds of progressing from opioid misuse to full dependence (OR 0.64, 95% CI 0.55-0.74)
  • This association reached genome-wide significance (p=4.30×10^-9) and was replicated in two independent cohorts
  • CNIH3 encodes a helper protein for AMPA-type glutamate receptors, brain signaling proteins involved in reward and learning
  • A allele carriers showed greater amygdala dampening in response to threatening faces, a phenotype linked to psychological resilience
  • Animal data across 23 mouse strains independently supported this gene region's role in physical morphine dependence

What the research says A genome-wide association study compared 1,167 opioid-dependent daily injectors to 161 opioid misusers who never progressed to daily injection, identifying five genome-wide significant variants in CNIH3 (cornichon family AMPA receptor auxiliary protein 3, a gene encoding a helper protein for AMPA glutamate receptors - ion channels that carry the brain's primary excitatory signals), with rs10799590 as the lead variant (p=4.30×10^-9; OR 0.64, 95% CI 0.55-0.74), meaning the A allele was associated with lower odds of reaching the opioid dependence endpoint. The association replicated in both the Yale-Penn genetic studies and the Study of Addiction: Genetics and Environment, each containing non-dependent opioid misusers alongside opioid-dependent individuals. Neuroimaging data from 312 participants further showed that A allele carriers displayed significantly greater right amygdala (a brain structure central to threat and emotional processing) habituation - reduced response strength over repeated exposures - to threat-related facial expressions, a phenotype associated with resilience to psychopathology; epigenetic annotation also predicted rs10799590 to be functional in fetal brain.

Reported associations

  • Opioid dependence progression (protective A allele): Associated with roughly 36% lower odds of progressing from opioid misuse to daily-injection dependence (OR 0.64, 95% CI 0.55-0.74; p=4.30×10^-9) in meta-analysis across three independent cohorts
  • Right amygdala habituation to threat: A allele carriers in the Duke Neurogenetics Study (n=312) showed significantly greater habituation of right amygdala activity to threat-related facial expressions, a phenotype associated with resilience to psychopathology
  • Morphine physical dependence (animal model): Computational genetic analyses across 23 mouse strains found significant correlations between haplotypes at this locus and physical dependence on morphine

Evidence quality The discovery comparison involved 1,167 opioid-dependent and 161 non-dependent opioid-misuser participants - modest by current GWAS standards - though the association reached genome-wide significance (p=4.30×10^-9) and was confirmed in two independent replication cohorts (Yale-Penn and SAGE), each including both dependent and non-dependent opioid misusers. Five variants at the locus achieved genome-wide significance in meta-analysis, adding internal consistency. Epigenetic annotation suggests rs10799590 may be functional in fetal brain. The neuroimaging substudy (n=312) provides biological plausibility but is observational and cannot establish causality. Animal model support is computational rather than experimental. No conflicting large-sample GWAS findings are reported in the available evidence. Overall, this represents preliminary-to-moderate evidence: genome-wide significant and replicated, but requiring confirmation in larger, ancestrally diverse samples.

Tissue-specific expression effects

  • CNIH3-AS2 (an antisense RNA gene at this locus): the ALT allele is associated with reduced expression in brain cortex and frontal cortex (Brodmann area 9) GTEx Portal
  • ENSG00000232628: reduced expression in both non-sun-exposed and sun-exposed skin GTEx Portal
  • LINC02813: reduced expression in tibial nerve GTEx Portal
  • DNAH14: increased expression in tibial nerve GTEx Portal
  • ENSG00000291068: increased expression in thyroid GTEx Portal

Lifestyle considerations No lifestyle considerations on file for this variant.

Frequently asked questions

What is the CNIH3 gene?

CNIH3 encodes a helper protein for AMPA-type glutamate receptors in the brain. Glutamate is the brain's main excitatory chemical signal, and AMPA receptors play roles in reward, learning, and how the brain adapts to repeated drug exposure.

What does the A allele of rs10799590 do?

In a genome-wide genetic study, people carrying the A allele had roughly 36% lower odds of progressing from opioid misuse to opioid dependence. Carriers also showed greater dampening of amygdala activity in response to threatening faces in brain imaging.

Is rs10799590 linked to opioid addiction?

A genome-wide association study found this variant in CNIH3 reached genome-wide significance in its association with the transition from opioid misuse to dependence, confirmed in two independent cohorts. This represents meaningful but preliminary evidence that requires replication in larger samples.

What is an AMPA receptor?

AMPA receptors are ion-channel proteins on brain cells that respond to glutamate, the brain's primary excitatory neurotransmitter. They are important for learning and memory, and the glutamate system has been implicated in how physical dependence on opioids develops.

What do the brain expression findings mean for this variant?

GTEx data show the variant is associated with reduced activity of CNIH3-AS2, a nearby gene, in brain cortex regions. This suggests the variant may influence gene expression in the brain, though the health significance of these expression changes is not yet established.